NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: PRAVEG · data 2026-11-01
Praveg Limited
In plain words
Price: 37.0% below its 52-week high of ₹325.
Delivery: 73.5% of traded shares were kept for delivery over the last 10 sessions, against 62.8% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹248 cr |
| Net profit (last 12 months) | ₹-19 cr |
| Sales growth, 3 years (yearly) | 41.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
ROE -2.5%, ROCE 1.6%, operating margin 1.3%: how much profit it earns on the money it uses.
Debt/equity 0.38, Profit growth — and sales growth 41.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-2.5%).
- Thin operating margin (1.3%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
21/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 16/30: Delivery 77.9% over the last 20 sessions vs 59.7% in the 40 before (1.3x); shares delivered per day 0.9x usual; 2 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 18 Sept 26Dividend Dividend ₹0.5 (ex-date) +0.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Praveg Limited debt-free?
Its latest reported debt-to-equity ratio is 0.38.
What is the 52-week high and low of Praveg Limited?
The 52-week high is ₹325 and the 52-week low is ₹202.51.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Praveg Limited | ₹204.91 | ₹539 cr | — | — | -2.5% | 1.6% | 0.38 | -24.4% |
| Hexagon Nutrition Limited | ₹54.11 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.1% |
| Wanbury Limited | ₹189.21 | ₹664 cr | 11.6 | — | 64.9% | 31.1% | 1.57 | -25.8% |
| Amanta Healthcare Limited | ₹163.56 | ₹632 cr | 43.3 | — | 9.4% | 11.5% | 1.11 | +33.5% |
| Infinium Pharmachem Ltd. | ₹281 | ₹438 cr | 36 | 3.6 | 10.5% | 13.5% | 0.19 | +8.0% |
| Albert David Ltd | ₹762.8 | ₹435 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
Compare PRAVEG with HEXAGON in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open PRAVEG in NSE Scanner →